Mangafodipir trisodium-enhanced magnetic resonance imaging for evaluation of pancreatic mass and mass-like lesions

Figure 1 T1-weighted axial SE contrast-unenhanced (A) and MnDPDP-enhanced (B) images of pancreatic adenocarcinoma with liver metastases. MnDPDP enhancement was not determined in the lesion while the normal parenchyma of the pancreas showed homogeneous contrast enhancement. MnDPDP- enhanced image showed the better delination of the tumor (thick arrows). Tiny liver metastases (thin arrows) were not determined on unenhanced MR image but on MnDPDP-enhanced MRI.

Figure 2 Unenhanced (A) and MnDPDP-enhanced (B) axial T1-weighted GRE images, unenhanced (C) and MnDPDP-enhanced (D) coronal T1-weighted SE images in pancreatic parenchyma out of lesion and liver parenchyma after MnDPDP infusion. Minimal contrast enhancement in the septa of mass was found on MnDPDP-enhanced images (B and D).

Figure 3 Contrast-unenhanced T1-weighted axial SE image demonstrating focal enlargement of the pancreatic head with a low signal intensity, simulating the appearence of pancreatic cancer (A) and MnDPDP-enhanced T1-weighted axial SE image showing heterogeneous and reduced contrast enhancement in this focal lesion (B).

Figure 4 Unenhanced (A) and MnDPDP-enhanced (B) axial T1-weighted SE images showing better delineation of the tumor after MnDPDP infusion.